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SCAFFOLD FOR BONE AND TISSUE REPAIR
IN MAMMALS

2
body comprising: biocompatible inorganic glass fibers each
having a fiber transverse dimension and a fiber lengthwise

FIELD OF THE INVENTION

dimension; and an interconnected porosity constituting

dimension which is at least about 10 times the fibertransverse
between about 10 vol.% and about 35 vol.% of the Scaffold

body; wherein each of the fibers has a diameter between about

This invention relates to a biocompatible scaffold for
implantation into mammals to facilitate bone and tissue
repair, regeneration, and proliferation.
BACKGROUND OF THE INVENTION

The use of tissue scaffold to facilitate the repair and
regrowth of bone and other tissue is known in the art, for
example, from U.S. Pat. No. 7.338,517 which discloses an
implantable scaffold with biopolymer fibrils aligned in heli
cal patterns of opposite directions.

20 and about 5000 microns; wherein the fibers are bonded

10

15

U.S. Pat. No. 7,416,564 describes a bone scaffold made

from porous ceramic Substrate of a material Such as Zirconia
which is then coated with a fluorapatite layer and a hydroxya
patite layer. The porous Substrate was prepared by dipping a
foam template into a slurry. The porosity is aligned irregularly
and randomly and does not run continuously along a longi
tudinal axis from one end of the object to the other end. The
fabrication requires repeated dipping and drying.
SUMMARY OF THE INVENTION

Briefly, therefore, the invention is directed to a tissue scaf
fold comprising a rigid scaffold body having a scaffold cen
lengthwise dimension which is greater than the scaffold
transverse dimension, the scaffold body having a compres
sive strength between about 20 and about 250 MPa and com
prising biocompatible inorganic glass fibers each having a
fiber transverse dimension and a fiber lengthwise dimension

30

35

sion; and an interconnected porosity constituting between
about 10 vol.% and about 35 vol. % of the scaffold body;
40

least about 10 times the fiber transverse dimension; and an

45

within the scaffold.

Other objects and features of the invention are in part
apparent and in part pointed out hereinafter.
FIG. 1A is an optical micrograph of a transverse cross
section of a scaffold of the invention formed by heating fibers
at 700° C. for a relatively shorter time than with the scaffold
FIGS. 1B and 1C are SEM photographs of a transverse
cross section of the scaffold of the invention formed by heat
ing fibers at 700° C. for a relatively longer time than with the
FIG. 2 is a photograph of a lengthwise cross section of the
scaffold of the invention showing lengthwise and parallel
alignment of fibers.
FIGS. 3A, 3B, and 3C are a series of photographs showing
the manufacturing progression of a unidirectional scaffold
from loose fibers to a self-bonded scaffold of the invention.

FIGS. 4A and 4B are photographs of a segment of scaffold
50

of the invention after immersion in an osteoblast cell culture

and MTT labeling.
FIGS. 5 and 6 are graphical plots of open porosity and
compressive strength data of scaffolds of the invention.
FIG. 7 is a photograph of a scaffold of the invention next to
55

interconnected porosity constituting between about 10 Vol.%
and about 35 Vol.% of the scaffold body; wherein the fibers
are bonded together; wherein each of the fibers has a diameter

a chicken bone.
FIGS. 8 and 9 are still frames extracted from videos taken

of experiments described in the working examples.
FIGS. 10, 12, and 13 are schematic depictions of alterna

between about 20 and about 5000 microns; and wherein at

least about 75 vol% of the fibers extend generally parallel to
the scaffold central axis, and are arranged to define open

% of the fibers extend generally in the direction of the scaffold
central axis, are generally free of helical orientation about the
scaffold central axis, and are arranged to define open channels
within the scaffold which allow fluid flow into and lengthwise

Scaffold in FIG. 1A.

the scaffold.

In another aspect the invention is directed to a tissue scaf
fold comprising a rigid scaffold body having a central axis, a
scaffold transverse dimension, and a scaffold lengthwise
dimension which is greater than the scaffold transverse
dimension, the scaffold body having a compressive strength
between about 20 and about 250 MPa and comprising: bio
compatible inorganic glass fibers each having a fiber trans
verse dimension and a fiber lengthwise dimension which is at

dimension; wherein the fibers have a diameter between about
20 and about 5000 microns; and wherein at least about 75 vol

in FIGS. 1B and 1C.

wherein each of the fibers has a diameter between about 20

together; and wherein at least about 75 vol% of the fibers
extend generally in the direction of the scaffold central axis,
are generally free of helical orientation about the scaffold
central axis, and are arranged to define open channels within
the scaffold which allow fluid flow into and lengthwise within

lengthwise within the scaffold.
In another aspect the invention is directed to a method for
making a tissue scaffold comprising: heating inorganic bio
compatible glass fibers in a mold to a temperature where the
fibers partially fuse to each other to form a rigid scaffold body
having a scaffold central axis, a scaffold transverse dimen
Sion, and a scaffold lengthwise dimension which is greater
than the scaffold transverse dimension, the scaffold body
having an interconnected porosity between about 10 Vol.%
and about 35 Vol.%, a compressive strength between about 20
and about 250 MPa; wherein the biocompatible glass fibers
each has a fiber transverse dimension and a fiber lengthwise

BRIEF DESCRIPTION OF THE FIGURES

which is at least about 10 times the fiber transverse dimen

and about 5000 microns; wherein the fibers are bonded

within the scaffold, which channels allow fluid flow into and

dimension which is at least about 10 times the fibertransverse

25

tral axis, a scaffold transverse dimension, and a scaffold

together; wherein at least about 75 vol% of the fibers extend
generally in the direction of the scaffold central axis, and are
arranged to define open channels lengthwise through a core

tive reinforced scaffold embodiments of the invention.
60

FIG. 11 is a photograph of a scaffold according to the
Schematic of FIG. 10.

channels within the scaffold which allow fluid flow into and

lengthwise within the scaffold.
The invention is also directed to a tissue scaffold compris
ing a scaffold body having a central axis, a scaffold transverse
dimension, and a scaffold lengthwise dimension which is
greater than the scaffold transverse dimension, the scaffold

DESCRIPTION OF PREFERRED
EMBODIMENTS
65

The tissue scaffold of the present invention is prepared
from fibers which are aligned so that a majority of the fibers
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are substantially aligned in a parallel direction. The scaffold is
prepared by placing and orienting fibers in a unidirectional
manner in a mold. The fibers in the mold are heated to a

temperature where the fibers soften and bond together. In one
preferred embodiment, the fibers are self bonded in the sense
that no adhesive, braze, or other external bonding agent is
used for bonding. An alternative embodiment employs a bio
compatible agent or adhesive to facilitate bonding, such that
the fibers are not self bonded, at least in part. Upon cooling,
the assemblage of bonded fibers is sufficiently rigid and
strong that the assemblage can be removed from the mold and
handled. The scaffold is sufficiently rigid that it can be
implanted into a mammal where it facilitates the repair and
regeneration of hard tissue Such as bone (including cortical
and cancellous) or soft tissue such as muscle, cartilage, skin,
organ, or other hard or soft tissue.
The orientation of the fibers in a lengthwise direction in the
self bonded scaffold provides lengthwise channels (or con
nected pores) among the fibers, which channels provide for
uptake into the scaffold of stem cells, growth factors, medi
cines, red blood cells and other bodily fluids and components
carried in bodily fluids. The fibers are arranged to define

10

from the central axis of the scaffold. So it is evident that this
15

vidual fibers to an orientation outside these 25, 15, and 10

25

30

the scaffold and enables fluids to flow from one end of the
scaffold to the other or to enter the scaffold from its surface

and transmit the liquid to its ends.
The invention in one embodiment employs fibers having a
diameter, prior to molding and softening, between about 20

35

40

450 microns, such as between about 100 and about 300

microns. In an alternative embodiment, the scaffold is pre
pared from fibers having diameters up to about 3000 or 5000
microns (3 to 5 mm), which can be deemed more akin to rods
than fibers in some contexts, but for purposes of the discus

45

sion of this invention fall within the definition of “fibers.”

FIG. 1A is an optical micrograph of a cross section of a
scaffold of the invention showing the self-bonded fibers and
pores after heating the fibers at 700° C. for 15 minutes. FIGS.
1B and 1C, which are SEM photographs of a transverse cross
section of a different scaffold of the invention having under
gone a greater degree of softening and bonding than the
scaffold of FIG. 1A, show that after molding and joining to a
greater degree (heating at 700° C. for 45 minutes), the trans
verse cross section of each fiberis no longerprecisely circular
as it is in a freshly formed fiber. Rather, the softening of the
fibers and fusing of adjacent fibers to each other imparts an
irregular and irregularly rounded shape to the fibers in trans

prior to machining.
In order to allow capillary action and channel-forming, the
scaffold theoretically contains at least three fibers, although
from FIG. 2 it can be seen that the scaffold typically com
prises dozens and even hundreds of fibers. It can also be seen
that the fibers lie generally lengthwise of the scaffold central
axis A (i.e., lie generally in the direction of the central axis)
and are generally free of helical orientation about the scaffold
central axis. This arrangement applies to at least about 75 Vol
% of the fibers and preferably to substantially all of the fibers.
The fibers shown here extend generally parallel to the scaffold
central axis A, which is also illustrated as axis B in FIG. 3C,

50

and axis C in FIG. 7B. This embodiment also manifests an

optional feature that at least about 75 vol% of the fibers
occupies the entire length of the scaffold; but in other embodi
ments this is not the case.
55

verse cross section. The transverse cross sections here reflect

joined fiber cross sections ranging in width loosely, diam

scaffold itself in certain embodiments is curved, bent, or

otherwise not straight, in which cases the central axis of the
scaffold to which the alignment of the fibers is within 25
degrees of parallel is also curved, bent, or otherwise not
straight. It will also be evident that in certain embodiments a
straight or curved scaffold will be machined into a more
complex shape as in FIGS. 7A and 7B, in which instance the
scaffold central axis refers to the central axis as molded and

and about 5000 microns, such as between about 50 and about

5000 microns. In one embodiment the scaffold is prepared
from fibers having diameters between about 100 and about

therefore in FIG. 2 that each fiber in the scaffold is not

absolutely straight, nor is it lying along an absolutely straight
line strictly parallel to all other fibers in the scaffold. And each
fiber is oriented generally in the same direction, but each is
not oriented in exactly the same direction. Moreover, the

outer surface of the interior or core of the scaffold. These

longitudinal and transverse channels exert significant capil
lary forces on a liquid which cause the liquid to be drawn into
the scaffold. This capillary action facilitates the distribution
of these fluids and components relatively uniformly through

co-alignment aspect does not require 100% precise co-align
ment of all fibers. The longitudinal co-alignment aspect also
allows for Some minor deviation of specific segments of indi
degree requirements. This is reflected in the requirement that
the longitudinal co-alignment is of each fiber along at least
75% of its length, rather than necessarily along its entire
length. So up to about 25% of the length of an individual fiber
may be misaligned because, for example, it was bent during
the scaffold-making process or otherwise. It can be seen

channels within the scaffold which facilitate fluid flow into

and lengthwise within the scaffold from one end to the other
end. The orientation also provides for channels in a transverse
direction generally perpendicular to the lengthwise direction
of the oriented fibers, to facilitate uptake of fluids from the

4
co-aligned. In this regard the fibers are co-aligned longitudi
nally, where “co-aligned longitudinally and the like phrases
(e.g., “in lengthwise co-alignment') as applied to a group of
adjacent, bundled, or joined fibers in this application means
that the alignment of each fiber in the group at any one place
along at least about 75% of its length does not deviate more
than about 25 degrees from parallel to the central axis of the
scaffold. In one preferred embodiment, each fiber in the group
at any one place along at least about 75% of its length does not
deviate more than about 15 degrees from parallel to the cen
tral axis of the scaffold. In another preferred embodiment,
each fiber in the group at any one place along at least about
75% of its length does not deviate more than about 10 degrees

60

The requirement of the invention that the fibers are co
aligned longitudinally contemplates that the fibers are posi
tioned so that they have a similar alignment, which similar
alignment may be straight, bent, or curved. In a separate and
distinct aspect of certain preferred embodiments, this com
mon alignment is limited to a generally straight alignment
along at least about 75%, 85%, or 95% of the length of the

eter—from about 50 to about 300 microns.

fibers. In other words, at least about 75%, 85%, or 95% of

The fibers in the scaffold are bonded together and therefore
are not loose fibers; but they retain their identities as separate
fibers as shown in FIG. 2, which is a photograph of a longi
tudinal cross section of a scaffold (heated at 700° C.) of the
invention. In one aspect of the invention, at least about 75 or
85% by volume of the fibers in the scaffold are longitudinally

each fiber is generally straight, i.e., at least about 75%, 85%,
or 95% of the length of each fiber has an alignment which is
within 10 degrees of a mean straight central axis for the fiber.
So up to 5%, 15%, or 25% of the length of each fiber may be
curved, bent, or otherwise deviate more than 10 degrees from
straight in relation to the overall fiber length, but the rest of

65
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amorphous or non-crystalline solid, for example made by
fusing a mixture of oxides such as SiO, BO, POs (known
as glass forming oxides) with basic oxides such as the alkali

5
each fiber is generally straight in that it so deviates less than
10 degrees. In one preferred embodiment, substantially the
entire length of each fiber is generally straight in that it devi
ates less than 10 degrees from the fiber's average central axis.
The “mean Straight central axis' is the imaginary central axis
for the fiber which is absolutely straight and is an average of
all axes along the fiber length.

and alkaline earth oxides. In an alternative embodiment, the

The fibers in the scaffold are selected to have characteris

tics Suitable for the specific application. In one embodiment,
the fibers have a length between about 6 mm and about 15 cm,

10

such as between about 12 mm and about 10 cm or between

about 25 mm and about 75 mm. Each fiber has a length which
is at least about 10 times its diameter. "Diameter' as used

herein refers to the fibers largest dimension transverse to its
length, and it does not imply that the fibers are perfectly

15

circular in cross section. Each fiber therefore has a fiber

lengthwise dimension which is at least about 10 times the
fiber transverse dimension, e.g., diameter. In one embodi
ment, the fiber length is selected so that all, substantially all,
or at least about 85 vol% of the individual fibers extend the

entire length of the scaffold. The fibers may be selected to
have a pre-molding, pre-joining length which corresponds to
the length of the scaffold. Or in most embodiments, the length
of the fibers is longer than the desired ultimate scaffold
length, and the scaffold is cut to the desired length after
molding and joining. In an alternative embodiment, the length
of a substantial portion (e.g., at least 40 vol%) or all of the
fibers is significantly less than the entire length of the scaf

25

30

fold.

FIGS. 1A, 1B, 1C, 4A and 4B also demonstrate the open
and interconnected porosity of the scaffold of the invention.
The scaffold is manufactured to have a sufficiently high open
and interconnected porosity from end to end of the scaffold to
facilitate capillary flow of fluids such as bodily fluids and
medicines and components they carry through the length of
the scaffold, as well as generally transverse from outside
walls of the scaffold into the scaffold interior in directions

35

immersed in or otherwise contacted with natural or simulated
40

fibers. And the scaffold is manufactured so that the ultimate

between about 10% and about 30%, or between about 10%

and about 25%. The porosity is controllable mainly by con
trolling the degree of softening of the fibers, in that highly
softened fibers fuse together more completely to a structure
with lower porosity. The degree of softening and fusing is
controlled by controlling the joining temperature and time.
Porosity is also affected by the fiber diameter and by the range
in fiber diameter within a given scaffold. Porosity tends to
increase with an increasing range in fiber diameter.
The scaffold of the invention in certain preferred embodi
ments for use in bone repair has a compressive strength
between about 20 and about 250 MPa, for example between
about 20 and about 180 MPa or between about 80 and about
140 MPa.

The fibers used in many embodiments of the invention are
glass where glass is defined as being at least 99 wt % an

of Rolla, Mo. In other embodiments, some or all of the fibers

may be bioinert rather than bioactive, such as 100% bioinert
fibers or a roughly 50/50 mix of bioinert and bioactive fibers.
In general, bioactive glass is one which contains calcium
and, when placed in contact with natural body fluids or simu
lated body fluids, forms a bicompatible calcium phosphate
compound Such as hydroxyapatite. When Such a glass is
body fluids which contain phosphate ions such as in a mam

generally transverse to the longitudinal dimension of the
porosity is low enough that the scaffold has required strength
for handling, implantation, and service after implantation. If
the porosity is too high, the scaffold risks breakage in service,
depending on where it is implanted and the loads it encoun
ters. In a preferred embodiment, the porosity as measured in
volume is between about 10% and about 35%, for example

fibers include glass ceramics fibers that contain both glassy
and crystalline regions which in many respects function in the
same manner as a fiber that is completely (100%) non-crys
talline. It is acceptable in some applications if the glass fiber
crystallizes during the bonding step. The fibers may alterna
tively be pre-reacted bioactive glasses Such as glass fibers
pre-reacted to have a thin Surface layer of hydroxyapatite.
These foregoing different types offibers are within a common
group which are referred to herein as "glass fibers.” In a
further alternative, the unidirectional scaffold comprises
crystalline fibers (such as titanium wires) that would also
provide a high amount of capillary action. Alternatively, the
scaffold comprises a mix of different types of fibers selected
from among these.
The fibers are preferably made from a material which is
inorganic and which is biocompatible in that the fibers do not
have adverse effects when implanted into mammals. Biocom
patible materials include both bioactive and bioinert materi
als. In certain preferred embodiments, the fibers are also of a
bioactive glass in that they are of a glass material which reacts
with phosphorus such as phosphorus in bodily fluids to form
hydroxyapatite. Bioactive glasses are known in the art, for
example, from U.S. Pat. No. 6,054,400; the entire disclosure
of which is incorporated herein by reference. Bioactive
glasses are available, for example, from Mo-Sci Corporation

45

50

55

mal, the glass dissolves, thereby releasing Ca" ions into the
solution. In this solution, Ca" ions react with PO, and OH

ions to form a calcium phosphate which has a relatively low
solubility limit in the aqueous phosphate Solution. As the
dissolution of the glass proceeds, the concentration of cal
cium phosphate increases in the Solution until the solubility
limit of calcium phosphate is exceeded and, as a consequence,
hydroxyapatite (a form of calcium phosphate) is deposited as
aporous layer on the outer Surface of the dissolving glass. The
formation of this porous hydroxyapatite layer on the glass
surface, however, does not prevent further dissolution of the
glass. Rather, the glass continues to dissolve and, as it does,
the thickness of the porous hydroxyapatite layer increases.
Eventually, the glass is completely reacted or transformed,
leaving only a porous hydroxyapatite Substance whose shape
and size are the same as the initial glass fiber. Hydroxyapatite
has crystallographic and chemical properties similar to those
of mammalian bone. For example, human bone is a composite
of fibrous protein, collagen, and hydroxyapatite.
The material for use in the invention is also selected to be

60

65

of a composition which is available in fibers or which can be
pulled into fibers. Glass fibers can be made several ways. For
example, glass fibers can be made by pulling by hand or with
use of a rotating drum directly from a melt, or they can be
pulled through abushing of aparticular size. The composition
is preferably selected to be of a type which softens to facilitate
self-joining at a temperature below its crystallization tem
perature. Suitable bioactive glasses include, for example
those listed in Table 1.

US 8,353,966 B2
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TABLE 1.

Weight Percent Composition of Bioactive Glasses
Li2O

Na2O

KO

MgO

CaO

B.O.

P-Os

SiO2

O
O
O
O
O
O
O
O
O
O
O
O
O
O
11.5
10.7
10

2O
18
12
6
18
15
2O
2O
25
15
6
6
6
21.5
O
O
O

10
9
15
12
6
12
10
10
5
15
12
12
12
O
O
O
O

5
O
5
5
2
2
2
5
2
2
5
5
5
O
O
O
O

10
14
11
2O
17
11
10
10
10
15
2O
2O
2O
21.5
10
15
2O

O
1
1
O
2
3
3
3
3
3
17.7
35.3
53
O
78.5
74.3
70

O
4
2
4
2
4
3
O
3
O
4
4
4
4
O
O
O

55
54
S4
S3
53
S3
52
52
52
50
35.3
17.7
O
S3
O
O
O

Glasses which crystallize under fiber-pulling conditions
and/or which crystallize at a temperature below that where
they soften sufficiently for joining such as 45S5 have some
limited applications here but are generally avoided in the
preferred embodiments because they become too brittle and
weak. Bioactive glasses such as 45S5 and other glasses that
crystallize quickly not allowing sufficient self-bonding to
occur may be bonded with sodium silicate or some other
bonding agent to forman alternative scaffold embodiment of
the invention; however the strength will likely be relatively
low in comparison with self-bonded scaffolds.
In forming the scaffold of the invention, a bundle of glass
fibers such as the 6.25 cm long loose cut fibers shown in FIG.
3A is placed as shown in 3B in a mold or similar vessel which,
upon softening, joining, and cooling of the glass, will impart
the desired final shape and strength to the scaffold. Each of the
bundles inserted as shown in FIG.3B weighs about 2.4 grams
and the mold is about 5.6 cm long. In one embodiment, this
vessel is a graphite mold Such as a hollowed out cylinder as
shown in 3B. The fibers are placed in the vessel tightly enough
to fill the vessel cavity, but not so tightly as to risk breakage of
the fibers or excessive densification. The vessel is then placed

5

10

15

and form a new microstructure within the individual self

bonded fibers is desirable in certain applications. It is also
within the scope of this invention to incorporate additives
Such as growth factors, medicines, etc. into the scaffold body
which perform a function Such as assist with tissue regrowth
or supplement reinforcement of the body. In most preferred
25

embodiments, such additives or reinforcements constitute
less than about 10 Vol.% of the scaffold, such that the fibers

and the porosity cumulatively constitute at least about 75 vol.
% of the scaffold body, for example at least about 90 Vol.%.

And in some embodiments there are no such additives or

30

reinforcements, such that the scaffold body consists essen
tially of the fibers and the porosity.
After the wax has been removed, the scaffolds are steril

35

ized. A preferred method among several possible is dry heat
sterilization. The scaffolds are placed in a clean glass vial,
covered with a clean aluminum foil cap, and heated to
approximately 300° C. for three to four hours. Upon cooling,
the sterile scaffolds are ready to be implanted.
Growth factors, medicines such as antibiotics, seeded cells

40

in a furnace and heated at a rate of about 20° C./min in the

presence of a suitable atmosphere such as air, oxygen, or
nitrogen. The temperature and the heating time are selected
depending on the glass composition to achieve Softening and
bonding of the fibers while avoiding too much bonding which
would not achieve the desired porosity. The joining is prefer
ably self-joining in that the softening of the glass accom
plishes joining and no added joining agents are employed.
That is, the scaffold body consists only of joined fiber ele
ments and no other elements. As a general proposition, the
vessel is heated to a temperature between about 500 and about
800° C. and held at that temperature for between about 5 and
about 60 minutes. For example, in one embodiment where the
scaffold is formed from type 13-93 glass fibers to a finished
dimension of about 62.5 mm long and about 6 mm in diam
eter, the vessel is heated to a temperature between about 695
and about 705 C. and held at that temperature for between
about 5 and about 45 minutes. After bonding, the vessel and
scaffold are cooled, preferably in air, at a rate which avoids
cracking of the bonded fibers, such as between about 10 and
about 30° C. per minute.

45

The scaffold is then removed from the vessel and cut to the
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desired length to yield the product shown in FIG.3C. Cutting
is accomplished, for example, by filling the pores with a wax,

8
cutting the scaffold to length with a sharp, non-burring (e.g.,
diamond) saw, and then chemically or thermally removing
the wax. Sharp corners and edges are avoided by making
clean cuts while the scaffold is impregnated with wax, or a
polish can be done with either grinding paper or a mechanical
polishing device Such as a Dremel tool, also done while wax
impregnated.
The scaffold can be pre-reacted in a phosphate solution
such as simulated body fluid (SBF) or an alkali phosphate
Solution to form a reacted Surface layer of hydroxyapatite,
prior to sterilization and implantation in a mammal. The
hydroxyapatite surface layer thickness can be controlled by
predetermined conversion kinetics of the glass in a phosphate
containing Solution. Heat treatment of the glass can induce
glass crystallization which may be beneficial in the formation
of glass-ceramics or ceramics. Chemical (acid) etching may
add surface roughness which could be beneficial to cell
attachment. Heat treating the glass to cause phase separation
to form multiple phases which could react at different rates

50
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or other biological material, liquids or gels of any type, coat
ings (particles, spheres, hollow spheres, thin film(s), fibers,
and hollow fibers), an interpenetrating phase such as a bio
degradable polymer or bone cement (PMMA) or other bio
logical polymer, other organic or inorganic materials, or any
combination may be added after sterilization to promote the
growth of tissues into the scaffold. Additional sterilization
may be required for Scaffolds that have had inorganic non
sterile components added, and the method of sterilization
may vary with the material(s) added.
In one alternative embodiment of the invention, a titanium
or other biocompatible Support such as a rod is incorporated
into the scaffold to provide additional mechanical strength, as
shown in FIGS. 10-13.
The unidirectional scaffold of the invention is suitable in

one aspect for forming a complete replacement bone or tissue
segment where the mammals original bone or other tissue
segment has been removed, crushed, decimated by disease or
the like. In another aspect the scaffold is suitable as a bridge
such as between about 2 mm and about 25 mm in length for
bridging two separated bone segments. The scaffold is
intended to serve as a temporary bridge for facilitating fluidic
(e.g., marrow) communication (or transport) between the
separated bone segments, thereby facilitating the healing of
the broken bones. The scaffold also serves as an internal splint
providing support for the bone fracture while the bone heals.
Example 1
Fibers of the bioactive glass type 13-93 (-2.4 grams) pro
duced at Missouri University of Science & Technology hav
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ing diameters in the range of about 50 to about 400 microns and a diameter of about 6 mm. The fibers were type 13-93
and lengths of about 62 mm were placed inside a graphite bioactive glass having a length of about 62 mm and diameters
mold formed by hollowing out a graphite cylinder. The mold ranging from about 50 to about 400 microns. The fibers were
was then placed in a furnace (Neytech Model 2-525) and oriented parallel to the longitudinal axis of the scaffold. The
heated in air to a temperature of about 700° C., where it was s tip of the scaffold was dipped in a glycerol solution (34 wt %
held for times ranging from 5 to 45 minutes. The heat source glycerol-66 wt % distilled water) as shown in FIG. 8. This
was discontinued and the mold cooled to room temperature at solution has a viscosity of 2.5 centipoises at 25°C., which is
an average cooling rate of about 30° C./min. Cylindrical in the average range for human blood. The purpose of this
scaffolds of unidirectional self-bonded fibers were removed
from the mold, sectioned, and photographed to provide the 10 experiment was to demonstrate the strong capillary forces
which this scaffold exerts upon a liquid resembling human
images in FIGS. 1A, 1B, and 1C. The diameter of the scaf blood.
folds was 6 mm. FIG. 1A depicts a scaffold heated for a
A roughly 40 second video of the experiment was filmed,
shorter period of time having a lower degree of self bonding,
higher porosity, and lower strength. FIGS. 1B and 1C depict and frames at 9, 11, 15, and 22 seconds are shown in FIGS.
a scaffold heated for a longer period of time, having a greater 8A, 8B, 8C, and 8D, respectively. These frames show pro
degree of self bonding, lower porosity, and greater strength. 5 gressively upward darkening of the scaffold, which demon
In 1B and 1C the pore size is approaching too small, thereby strates rapid capillary uptake of the Solution and its compo
inhibiting fluid flow in the scaffold in comparison to FIG. 1A.
nents into the scaffold, and that the scaffold of the invention
Open pores of at least about 100 microns in cross section are has strong capillary uptake of fluid in the direction of the
required for bone growth.
longitudinal axis of the fiber scaffold.
2O
Example 2
Example 7
A 6 mm diameter by 20 mm thick section of a unidirec
tional scaffold produced according to Example 1 was placed
in a culture of osteoblast cells for four hours. MTT labeling
was then performed on the section and photographs were
taken (FIGS. 4A and 4B). The dark spots are due to the uptake

25

diameter of about 50 to 400 microns. The fibers were oriented

of viable osteoblast-like cells into the scaffold.
EXample
le 3

Undirectional glass scaffolds were prepared in accordance
with Example 1 with joining/heating times at 700° C. of 5, 15,
30, and 45 minutes. The open porosity of each scaffold was
then determined by the Archimedes liquid displacement
method to be 35, 25, 15, and 18 vol%, respectively; see FIG.
5. This degree of open porosity is within the range of human

A cylindrical, unidirectional glass scaffold was prepared in
accordance with Example 1 having a length of about 62 mm
and a diameter of about 6 mm. The fibers were type 13-93
bioactive glass fibers having a length of about 62 mm and a

30

35

parallel to the longitudinal axis of the scaffold.
An eyedropper was used to drop the same water-glycerol
solution as described in Example 6 onto the external surface
of the scaffold as shown in FIG.9 for the purpose of demon
strating the rapid capillary action of the scaffold in a direction
perpendicular to the longitudinal axis of the scaffold. The
Solution was dropped fairly quickly drop-by-drop onto the
external surface of the scaffold until the scaffold became

saturated with the solution. A video of this experiment was
made over a 50 second period. Frames at 4 seconds (0 drops),
12 seconds (3 drops), 18 seconds (6 drops), and 43 seconds
and 45 minutes.
(19 drops) are shown in FIGS. 9A, 9B, 9C, and 9D, respec
Example 4
40 tively. These frames show rapid capillary uptake of the solu
tion and its components into the scaffold in both the length
Unidirectional glass scaffolds were prepared inaccordance wise and transverse directions. This experiment demonstrates
with Example 1 with joining/heating times at 700° C. of 5, 15, the scaffolds high affinity for the liquid and that the scaffold
30, and 45 minutes. The average compressive strength of each retained most of the drops before becoming saturated. At the
scaffold was then determined by mechanical compression 45 conclusion of this experiment most of the liquid was retained
testing (Instron mechanical test instrument Model 4204 with in the scaffold and very little of the solution had dripped out
a crosshead speed of 0.5 mm/min) to be 20, 80, 130, and 112 of the scaffold into the bowl, as shown in 9D.
MPa, respectively, see FIG. 6. This demonstrates that com
Example 8
pressive strengths within the range of human cortical bone
cortical bone and was achieved for scaffolds heated for 15, 30,

were achieved for the scaffolds heated for 30 and 45 minutes.

50

Example 5
A unidirectional scaffold was prepared in accordance with
this invention by molding, bonding, cooling, and then
machining to mimic the configuration of a chicken bone. FIG.
7 shows the scaffold next to leg bone of a chicken. The
scaffold of the invention, which is the lighter-colored of the
two specimens closer to the ruler in FIG. 7, has a length of
about 50 mm. This unidirectional scaffold is composed of
fibers which were oriented parallel to the longitudinal axis of
this object.
Example 6
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bundle of fibers, and heated so that the fibers self-bonded and
65

A unidirectional cylindrical glass scaffold was prepared in
accordance with Example 1 having a length of about 62 mm

A unidirectional scaffold was prepared generally in accor
dance with Example 1 having a length of about 62 mm and a
diameter of about 6 mm. The fibers were type 13-93 bioactive
glass fibers having a length of about 62 mm and a diameter of
about 50 to 400 microns. The fibers were oriented in longi
tudinal co-alignment defining the length of the scaffold with
an added reinforcing rod placed at the center of the fibers prior
to self-bonding. FIG. 10 is a schematic pictorial demonstrat
ing this concept of placing a reinforcement of Ti or other
metal or alloy or Supporting material in the center of a self
bonded unidirectional bioactive glass fiber scaffold. FIG. 11
is a photograph of the reinforced unidirectional bioactive
glass scaffold prepared with a Tirod placed in the center of a
also attached to the rod, in accordance with this example.
FIG. 12 is a schematic pictorial demonstrating an alterna
tive concept of filling a hollow reinforcing tube of Tior other
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metal or alloy or polymer including biodegradable polymers
such as PCL or PLA or other supporting material with unidi
rectional glass fiber followed by self-bonding to form the
scaffold. The tube is, for example, made of titanium or any

12
into and lengthwise within the scaffold; and wherein the
fibers are self-bonded together in that adjacent longitu
dinally aligned fibers are fused together.
2. The scaffold of claim 1 wherein the fibers are bioactive

other reinforcing material with similar thermal expansion 5 glass fibers.

properties of the glass so the scaffold bonds to the tube as the
fibers self-bond. This may be beneficial in promoting bone
ingrowth in prosthesis Such as hip implants by inserting glass
fibers into and around the implant as a means for improved
bone attachment and ingrowth. FIG. 12 demonstrates an
aspect of the invention, as with FIGS. 1A, 1B, and 1C, in that
the fibers extending lengthwise of the scaffold central axis
define channels lengthwise through a core within the scaffold.

10

This is distinct from the alternative in FIG. 11, in which the

core is occupied by a reinforcing rod rather than by channel
defining fibers.
FIG. 13 is a schematic pictorial demonstrating a further
alternative concept of a unidirectional bioactive glass scaffold
filled with a polymer phase. Suitable polymers include those
such as bone cement (PMMA) or biodegradable polymers
such as PCL or PLA, as the polymer phase is used for sus
tained reinforcement (PMMA) or an initial reinforcement
followed by a slow degradation of biodegradable polymer
allowing new tissue to fill in with time. These methods asso
ciated with FIGS. 10-13 can be practiced individually or in
any combination for constructing or implementing a rein
forced unidirectional bioactive glass scaffold. These embodi
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invention, it is intended that all matter contained in the above

1. A tissue scaffold for repair and regeneration of bone hard
tissue or muscle, skin, or organ Soft tissue, the scaffold com
prising:
a rigid scaffold body having a scaffold central axis, a scaf
fold transverse dimension, and a scaffold lengthwise
dimension which is greater than the scaffold transverse
dimension, the scaffold body having a compressive
strength between about 20 and about 250 MPa and com
prising:
biocompatible inorganic glass fibers each having a fiber
transverse dimension and a fiber lengthwise dimension

45
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13. The scaffold of claim 1 wherein each fiberamong the at
least about 75 vol% of fibers has an alignment along at least
about 75% of its length which does not deviate more than
about 10 degrees from parallel to the central axis of the

fiber.

scaffold; and

wherein each fiber among the 75 vol% of fibers has an
alignment along at least 85% of its length which is
within 10 degrees of a mean straight central axis for said
55

dimension; and
60

wherein each of the fibers has a diameter between about 20

and about 5000 microns;

wherein at least about 75 vol% of the fibers are longitudi
nally co-aligned and liegenerally lengthwise of the scaf
fold central axis, are generally free of helical orientation
about the scaffold central axis, and are arranged to define
open channels within the scaffold which allow fluid flow

8. The scaffold of claim 1 wherein the scaffold body con
sists essentially of the longitudinally co-aligned, bonded
together glass fibers and the porosity.
9. The scaffold of claim 1 wherein the fibers and the poros
ity cumulatively constitute at least about 75 Vol.% of the
scaffold body.
10. The scaffold of claim 1 wherein the scaffold body
further comprises a reinforcement of the scaffold body.
11. The scaffold of claim 1 wherein the scaffold body
further comprises a reinforcement to which some fibers
among said fibers of the scaffold body are bonded.
12. The scaffold of claim 1 wherein each fiberamong the at
least about 75 vol% of fibers has an alignment along at least
about 75% of its length which does not deviate more than
about 25 degrees from parallel to the central axis of the
wherein each fiber among the 75 vol% of fibers has an
alignment along at least 75% of its length which is
within 10 degrees of a mean straight central axis for said

which is at least about 10 times the fiber transverse

an interconnected porosity constituting between about 10
vol.% and about 35 vol.% of the scaffold body;

7. The scaffold of claim 1 wherein each fiberamong the 75
vol% of fibers has an alignment along at least 95% of its
length within 10 degrees of a mean Straight central axis for

scaffold; and

description and shown in the accompanying drawings shall be
interpreted as illustrative and not in a limiting sense.
The invention claimed is:

scaffold.

said fiber.

“the' and “said are intended to mean that there are one or

more of the elements. The terms “comprising”, “including
and “having are intended to be inclusive and mean that there
may be additional elements other than the listed elements.
AS Various changes could be made in the above composi
tions and methods without departing from the scope of the

4. The scaffold of claim 1 wherein each fiberamong the at
least about 75 vol% of fibers has an alignment along at least
about 75% of its length which does not deviate more than
about 10 degrees from parallel to the central axis of the

axis for said fiber.

attained.

When introducing elements of the present invention or the
preferred embodiments(s) thereof, the articles “a”, “an',

scaffold.

5. The scaffold of claim 1 wherein each fiberamong the at
least about 75 vol% of fibers is generally straight.
6. The scaffold of claim 1 wherein each fiberamong the 75
vol% of fibers has an alignment along at least 75% of its
length which is within 10 degrees of a mean straight central

ments are distinct from the embodiments featured in FIGS. 8

and 9, where the scaffold body consists essentially of the
fibers and porosity as described herein.
In view of the above, it will be seen that the several objects
of the invention are achieved and other advantageous results

3. The scaffold of claim 1 wherein each fiberamong the at
least about 75 vol% of fibers has an alignment along at least
about 75% of its length which does not deviate more than
about 25 degrees from parallel to the central axis of the
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fiber.

14. A tissue scaffold for repair and regeneration of bone
hard tissue or muscle, skin, or organ soft tissue, the scaffold
comprising:
a rigid scaffold body having a central axis, a scaffold trans
verse dimension, and a scaffold lengthwise dimension
which is greater than the scaffold transverse dimension,
the scaffold body having a compressive strength
between about 20 and about 250 MPa and comprising:
biocompatible inorganic glass fibers each having a fiber
transverse dimension and a fiber lengthwise dimension
which is at least about 10 times the fiber transverse

dimension; and
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an interconnected porosity constituting between about 10
vol.% and about 35 vol.% of the scaffold body;
wherein each of the fibers has a diameter between about 20

and about 5000 microns;

wherein at least about 75 vol% of the fibers extend gener
ally parallel to the scaffold central axis, and are arranged
to define open channels within the scaffold which allow
fluid flow into and lengthwise within the scaffold; and
wherein the fibers are self-bonded together in that adja
cent longitudinally aligned fibers are fused together.

10

which is at least about 10 times the fiber transverse

15. The scaffold of claim 14 wherein the fibers are bioac

tive glass fibers.
16. The scaffold of claim 14 wherein each fiber among the
at least about 75 vol% of fibers has an alignmentalong at least
about 75% of its length which does not deviate more than
about 25 degrees from parallel to the central axis of the

dimension; and
15

and about 5000 microns;

wherein at least about 75 vol% of the fibers are longitudi
nally co-aligned and lie generally lengthwise of the scaf
fold central axis, and are arranged to define open chan
nels lengthwise through a core within the scaffold,
which channels allow fluid flow into and lengthwise

17. The scaffold of claim 14 wherein each fiber among the
at least about 75 vol% of fibers has an alignmentalong at least
about 75% of its length which does not deviate more than
about 10 degrees from parallel to the central axis of the
18. The scaffold of claim 14 wherein each fiber among the
at least about 75 vol% of fibers is generally straight.
19. The scaffold of claim 14 wherein each fiber among the
75 vol% of fibers has an alignment along at least 75% of its
length which is within 10 degrees of a mean straight central

within the scaffold; and wherein the fibers are self
25

28. The scaffold of claim 27 wherein the fibers are bioac
30

35

said fiber.

21. The scaffold of claim 14 wherein the scaffold body
further comprises a reinforcement of the scaffold body.
22. The scaffold of claim 14 wherein the scaffold body
further comprises a reinforcement to which some fibers
among said fibers of the scaffold body are bonded.
23. The scaffold of claim 14 wherein each fiberamong the
at least about 75 vol% of fibers has an alignmentalong at least
about 75% of its length which does not deviate more than
about 25 degrees from parallel to the central axis of the

40

dimension; and
45

and about 5000 microns;
50
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scaffold; and

wherein each fiber among the 75 vol% of fibers has an
alignment along at least 85% of its length which is
within 10 degrees of a mean straight central axis for said

60

fiber.

25. The scaffold of claim 14 wherein the scaffold body
consists essentially of the glass fibers and the porosity.
26. The scaffold of claim 14 wherein the fibers and the

porosity cumulatively constitute at least about 75 Vol.% of
the scaffold body.

an interconnected porosity constituting between about 10
vol.% and about 35 vol.% of the scaffold body;
wherein each of the fibers has a diameter between about 20

fiber.

24. The scaffold of claim 14 wherein each fiberamong the
at least about 75 vol% of fibers has an alignmentalong at least
about 75% of its length which does not deviate more than
about 10 degrees from parallel to the central axis of the

29. The scaffold of claim 27 wherein at least about 75 vol

% of the fibers occupies the entire length of the scaffold.
30. A tissue scaffold comprising:
a rigid scaffold body having a scaffold central axis, a scaf
fold transverse dimension, and a scaffold lengthwise
dimension which is greater than the scaffold transverse
dimension, the scaffold body having a compressive
strength between about 20 and about 250 MPa and com
prising:
biocompatible inorganic glass fibers each having a fiber
transverse dimension and a fiber lengthwise dimension
which is at least about 10 times the fiber transverse

scaffold; and

wherein each fiber among the 75 vol% of fibers has an
alignment along at least 75% of its length which is
within 10 degrees of a mean straight central axis for said

bonded together in that adjacent longitudinally aligned
fibers are fused together.
tive glass fibers.

axis for said fiber.

20. The scaffold of claim 14 wherein each fiberamong the
75 vol% of fibers has an alignment along at least 95% of its
length within 10 degrees of a mean Straight central axis for

an interconnected porosity constituting between about 10
vol.% and about 35 vol.% of the scaffold body;
wherein each of the fibers has a diameter between about 20

scaffold.

scaffold.

14
27. A tissue scaffold for repair and regeneration of bone
hard tissue or muscle, skin, or organ soft tissue, the scaffold
comprising:
a scaffold body having a central axis, a scaffold transverse
dimension, and a scaffold lengthwise dimension which
is greater than the scaffold transverse dimension, the
Scaffold body comprising:
biocompatible inorganic glass fibers each having a fiber
transverse dimension and a fiber lengthwise dimension
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wherein at least about 75 vol% of the fibers are longitudi
nally co-aligned and lie generally lengthwise of the scaf
fold central axis, are generally free of helical orientation
about the scaffold central axis, and are arranged to define
open channels within the scaffold which allow fluid flow
into and lengthwise within the scaffold; wherein the
fibers are self-bonded together in that adjacent longitu
dinally aligned fibers are fused together, and
wherein the scaffold further comprises a biocompatible
support rod incorporated into the scaffold to provide
additional mechanical strength.
31. A tissue scaffold comprising:
a rigid scaffold body having a scaffold central axis, a scaf
fold transverse dimension, and a scaffold lengthwise
dimension which is greater than the scaffold transverse
dimension, the scaffold body having a compressive
strength between about 20 and about 250 MPa and com
prising:
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biocompatible inorganic glass fibers each having a fiber
transverse dimension and a fiber lengthwise dimension

16
fold central axis, are generally free of helical orientation
about the scaffold central axis, and are arranged to define

which is at least about 10 times the fiber transverse

open channels within the scaffold which allow fluid flow

dimension; and

into and lengthwise within the scaffold; and

an interconnected porosity constituting between about 10
vol.% and about 35 vol.% of the scaffold body;

wherein each of the fibers has a diameter between about 20
and about 5000 microns;

wherein the fibers are bonded together;
wherein at least about 75 vol% of the fibers are longitudi
nally co-aligned and liegenerally lengthwise of the scaf-

wherein the biocompatible glass fibers comprise both bio
active fibers and bioinert fibers.

32. The ti
ffold of claim 31 wherein the bi
. The t1SSue scalIola oi claim 31 w erein the blocompat

ible Support rod is titanium.
33. The tissue scaffold of claim 31 wherein the fibers are
'' attached to the rod.
k
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